HPV vaccine combo shows promise against head and neck cancer
NCT ID NCT05286060
First seen Feb 12, 2026 · Last updated Apr 30, 2026 · Updated 11 times
Summary
This study tests whether combining an HPV DNA vaccine with immune-boosting drugs can shrink advanced head and neck cancers caused by HPV types 16 or 18. About 56 adults with resectable tumors will receive the treatment before surgery. The main goal is to see if the tumor has fewer than 10% living cancer cells after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei University Health System, Severance Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.